tiprankstipranks
Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
Blurbs

Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)

Wedbush analyst Laura Chico maintained a Buy rating on Pharvaris (PHVSResearch Report) today and set a price target of $35.00. The company’s shares closed yesterday at $22.27.

According to TipRanks, Chico is a 3-star analyst with an average return of 2.1% and a 46.85% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Praxis Precision Medicines, and Pharvaris.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pharvaris with a $33.80 average price target, implying a 51.77% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $50.00 price target.

The company has a one-year high of $33.00 and a one-year low of $7.93. Currently, Pharvaris has an average volume of 107.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pharvaris (PHVS) Company Description:

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles